Clinical Trial

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-05-09
notable Trial sites expanded: 0 -> 26 locations 2026-05-09
Trial Details
NCT Number NCT07450547
Lead Sponsor Anagram Therapeutics, Inc.
Conditions Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Enrollment 113 participants
Start Date 2026-04-24
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-11